Catalyst overview
Research summary
This catalyst tracks a Phase 1 update for SGR-3515 in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
5/1/24- FDA cleared IND application. 7/31/24- Initiates Ph 1 dose-escalation trial. 10/23/24- New preclinical data presentation at ENA 2024. 8/6/25- Initial data in Q4 2025. 11/05/25:- Ph1 study progressing; initial clinical data now expected H1 2026 as dose escalation continues. 02/25/26:- Plan to present initial SGR-3515 Ph1 data in Q2 2026; exploring strategic partnerships. 05/05/26:- Preliminary Ph1 AACR data: intermittent dosing well tolerated; 65% disease control at ≥100 mg; partnering discussions ongoing. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.